- Kiniksa Pharmaceuticals (NASDAQ:KNSA) has announced a commercial supply agreement with Regeneron (NASDAQ:REGN) giving the latter the exclusive right to manufacture and supply rilonacept for Kiniksa’s U.K. subsidiary.
- The two companies had entered into a license agreement in September 2017 with Kiniksa having the exclusive license to develop and commercialize rilonacept.
- After an asset transfer agreement between the company and Kiniksa’s U.K. subsidiary, in January 2021, the company had assigned the license agreement to Kiniksa U.K. which then entered into a commercial supply agreement with Regeneron on March 1, 2021.
- Effective February 26, the supply agreement provides Kiniksa UK to use rilonacept for its clinical development and commercialization activities.
- In June 2020, Kiniksa announced positive Phase 3 data for rilonacept in patients with recurrent pericarditis.